STOCK TITAN

[Form 4] Insmed, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Magnera (MAGN) Q3 FY25 10-Q highlights post-merger scale but strained profitability. Net sales rose 51% YoY to $839 million (YTD $2.37 billion, +45%), mainly from the Nov-24 Glatfelter acquisition; organic volume slipped ~5%. Cost of goods sold jumped 53%, squeezing margin and cutting operating income 24% to $13 million. A new $1.99 billion debt stack pushed quarterly interest expense to $37 million, swinging the quarter to a $(18 million) loss (-$0.51/sh) versus $19 million profit last year; YTD loss is $(119 million).

Cash climbed to $276 million, but YTD operating cash flow was only $7 million; management still targets FY25 free cash flow of $75-95 million on ~$75 million capex. Leverage now approaches ~5× EBITDA, though covenants are solely negative. Integration/restructuring charges ran $14 million this quarter ($69 million YTD); expected annual synergies are $55 million and a $20 million capacity rationalisation is planned. Segment view: Americas revenue +22% to $473 million, margin 2.5%; Rest-of-World revenue +118% to $366 million, near breakeven. A $50 million currency-translation gain lifted comprehensive income to $32 million. Shares outstanding: 35.6 million (6 Aug 25).

Magnera (MAGN) Q3 FY25 10-Q evidenzia una crescita post-fusione ma una redditività sotto pressione. Le vendite nette sono aumentate del 51% su base annua, raggiungendo 839 milioni di dollari (YTD 2,37 miliardi di dollari, +45%), principalmente grazie all'acquisizione di Glatfelter a novembre 2024; il volume organico è diminuito di circa il 5%. Il costo del venduto è aumentato del 53%, comprimendo il margine e riducendo l'utile operativo del 24% a 13 milioni di dollari. Un nuovo indebitamento da 1,99 miliardi di dollari ha portato le spese per interessi trimestrali a 37 milioni di dollari, trasformando il trimestre in una perdita di 18 milioni di dollari (-0,51 dollari per azione) rispetto a un utile di 19 milioni dell'anno precedente; la perdita YTD è di 119 milioni di dollari.

La liquidità è salita a 276 milioni di dollari, ma il flusso di cassa operativo YTD è stato solo di 7 milioni; la direzione prevede ancora un flusso di cassa libero per l'anno fiscale 25 tra 75 e 95 milioni di dollari con un capex di circa 75 milioni. La leva finanziaria si avvicina ora a circa 5× EBITDA, sebbene i covenant siano esclusivamente negativi. Le spese di integrazione/ristrutturazione sono state di 14 milioni questo trimestre (69 milioni YTD); le sinergie annuali previste sono di 55 milioni e si pianifica una razionalizzazione della capacità da 20 milioni. Vista per segmento: ricavi Americas +22% a 473 milioni di dollari, margine 2,5%; ricavi Rest-of-World +118% a 366 milioni, quasi in pareggio. Un guadagno da traduzione valutaria di 50 milioni ha portato il reddito complessivo a 32 milioni. Azioni in circolazione: 35,6 milioni (6 agosto 2025).

Magnera (MAGN) Q3 FY25 10-Q destaca crecimiento tras la fusión pero rentabilidad ajustada. Las ventas netas aumentaron un 51% interanual hasta 839 millones de dólares (YTD 2,37 mil millones, +45%), principalmente por la adquisición de Glatfelter en noviembre de 2024; el volumen orgánico cayó aproximadamente un 5%. El costo de bienes vendidos subió un 53%, presionando el margen y reduciendo el ingreso operativo un 24% a 13 millones de dólares. Una nueva deuda de 1,99 mil millones de dólares elevó el gasto por intereses trimestral a 37 millones, convirtiendo el trimestre en una pérdida de 18 millones de dólares (-0,51 dólares por acción) frente a una ganancia de 19 millones el año pasado; la pérdida YTD es de 119 millones.

El efectivo aumentó a 276 millones, pero el flujo de caja operativo YTD fue solo de 7 millones; la gerencia sigue apuntando a un flujo de caja libre para el FY25 de 75-95 millones con un capex de alrededor de 75 millones. El apalancamiento ahora se acerca a ~5× EBITDA, aunque los convenios son solo negativos. Los cargos por integración/restructuración fueron de 14 millones este trimestre (69 millones YTD); las sinergias anuales esperadas son de 55 millones y se planea una racionalización de capacidad de 20 millones. Vista por segmento: ingresos en Americas +22% a 473 millones, margen 2,5%; ingresos en Rest-of-World +118% a 366 millones, casi en equilibrio. Una ganancia por traducción de moneda de 50 millones elevó el ingreso integral a 32 millones. Acciones en circulación: 35,6 millones (6 ago 25).

Magnera (MAGN) FY25 3분기 10-Q, 합병 후 규모 확대에도 수익성은 압박. 순매출은 전년 대비 51% 증가한 8억 3,900만 달러(연초부터 23억 7천만 달러, +45%)로, 주로 2024년 11월 Glatfelter 인수에 기인하며, 유기적 물량은 약 5% 감소했다. 매출원가는 53% 급증해 마진을 압박했고, 영업이익은 24% 감소한 1,300만 달러에 그쳤다. 신규 19억 9천만 달러 부채로 분기 이자 비용이 3,700만 달러로 증가해, 이번 분기는 1,800만 달러 손실(주당 -0.51달러)로 전년 1,900만 달러 이익에서 적자 전환했다; 연초부터 손실은 1억 1,900만 달러다.

현금은 2억 7,600만 달러로 증가했으나, 연초부터 영업 현금 흐름은 700만 달러에 불과하다; 경영진은 여전히 FY25 자유 현금 흐름 7,500만~9,500만 달러를 목표로 하며, 약 7,500만 달러의 자본 지출을 계획 중이다. 레버리지는 현재 약 5배 EBITDA에 근접했으며, 계약 조건은 부정적 조항만 존재한다. 통합 및 구조조정 비용은 이번 분기에 1,400만 달러(연초부터 6,900만 달러) 발생했으며, 연간 시너지 효과는 5,500만 달러, 2,000만 달러 규모의 생산능력 합리화가 계획되어 있다. 부문별로는 미주 지역 매출이 22% 증가한 4억 7,300만 달러, 마진 2.5%; 기타 지역 매출은 118% 증가한 3억 6,600만 달러로 거의 손익분기점에 도달했다. 5,000만 달러의 환율 변동 이익으로 총포괄손익은 3,200만 달러가 되었다. 발행 주식 수: 3,560만 주(2025년 8월 6일 기준).

Magnera (MAGN) Q3 FY25 10-Q met en lumière une croissance post-fusion mais une rentabilité sous pression. Les ventes nettes ont augmenté de 51 % en glissement annuel pour atteindre 839 millions de dollars (YTD 2,37 milliards, +45 %), principalement grâce à l'acquisition de Glatfelter en novembre 2024 ; le volume organique a diminué d'environ 5 %. Le coût des marchandises vendues a bondi de 53 %, comprimant la marge et réduisant le résultat d'exploitation de 24 % à 13 millions de dollars. Une nouvelle dette de 1,99 milliard de dollars a fait grimper les charges d'intérêts trimestrielles à 37 millions, entraînant une perte trimestrielle de 18 millions de dollars (-0,51 $/action) contre un bénéfice de 19 millions l'an dernier ; la perte YTD est de 119 millions.

La trésorerie est montée à 276 millions, mais le flux de trésorerie opérationnel YTD n'était que de 7 millions ; la direction vise toujours un flux de trésorerie libre FY25 de 75-95 millions avec un capex d'environ 75 millions. L'effet de levier approche désormais environ 5× l’EBITDA, bien que les engagements soient uniquement négatifs. Les charges d’intégration/restructuration se sont élevées à 14 millions ce trimestre (69 millions YTD) ; les synergies annuelles attendues sont de 55 millions et une rationalisation de capacité de 20 millions est prévue. Vue par segment : chiffre d’affaires Amériques +22 % à 473 millions, marge 2,5 % ; chiffre d’affaires Reste du Monde +118 % à 366 millions, proche de l’équilibre. Un gain de change de 50 millions a porté le résultat global à 32 millions. Actions en circulation : 35,6 millions (6 août 25).

Magnera (MAGN) Q3 FY25 10-Q zeigt Wachstum nach Fusion, aber unter Druck stehende Profitabilität. Der Nettoumsatz stieg im Jahresvergleich um 51 % auf 839 Millionen US-Dollar (YTD 2,37 Milliarden, +45 %), hauptsächlich durch die Übernahme von Glatfelter im November 2024; das organische Volumen sank um ca. 5 %. Die Herstellungskosten stiegen um 53 %, was die Marge belastete und das Betriebsergebnis um 24 % auf 13 Millionen US-Dollar drückte. Ein neuer Schuldenberg von 1,99 Milliarden US-Dollar erhöhte die Quartalszinsaufwendungen auf 37 Millionen US-Dollar, wodurch das Quartal mit einem Verlust von 18 Millionen US-Dollar (-0,51 US-Dollar je Aktie) abschloss, im Vergleich zu einem Gewinn von 19 Millionen im Vorjahr; der YTD-Verlust beträgt 119 Millionen.

Barmittel stiegen auf 276 Millionen US-Dollar, der operative Cashflow YTD betrug jedoch nur 7 Millionen; das Management peilt weiterhin einen Free Cashflow für FY25 von 75-95 Millionen US-Dollar bei etwa 75 Millionen Capex an. Die Verschuldung nähert sich nun etwa dem 5-fachen EBITDA, wobei die Covenants ausschließlich negativ sind. Integrations- und Restrukturierungskosten beliefen sich in diesem Quartal auf 14 Millionen US-Dollar (69 Millionen YTD); erwartete jährliche Synergien betragen 55 Millionen, und eine Kapazitätsanpassung von 20 Millionen ist geplant. Segmentansicht: Americas-Umsatz +22 % auf 473 Millionen US-Dollar, Marge 2,5 %; Rest-of-World-Umsatz +118 % auf 366 Millionen, nahezu ausgeglichen. Ein Währungsumrechnungsgewinn von 50 Millionen erhöhte das Gesamtergebnis auf 32 Millionen. Ausstehende Aktien: 35,6 Millionen (6. Aug. 25).

Positive
  • Revenue up 51% YoY to $839 million, demonstrating immediate scale benefits from Glatfelter acquisition.
  • Cash balance $276 million plus undrawn $350 million revolver provide liquidity headroom.
  • Management projects $55 million annual cost synergies and FY25 free cash flow of $75-95 million.
  • Currency translation gain $50 million lifted comprehensive income into positive territory.
Negative
  • Quarterly net loss $(18 million) vs $19 million profit prior year; YTD loss $(119 million).
  • Long-term debt ballooned to $1.99 billion, raising interest expense to $37 million (vs $1 million).
  • Operating cash flow only $7 million YTD, casting doubt on FCF guidance.
  • Organic volumes declined ~5% and pricing eroded, indicating underlying demand softness.
  • $69 million YTD integration/restructuring costs continue to pressure margins.

Insights

TL;DR: Strong top-line boost from Glatfelter deal, but debt-fuelled interest and integration costs drive losses; cash adequate near-term.

The 51% revenue surge confirms the strategic logic of adding Glatfelter’s fiber portfolio, yet underlying demand is soft (-5% organic volume, lower pricing). Gross margin fell ~520 bps as purchase-accounting step-ups and inflation offset scale benefits. Interest coverage is now below 1×, reflecting $1.6 billion fresh borrowings and two secured note issues; absence of maintenance covenants limits default risk but constrains future financing flexibility. Cash of $276 million plus an unused $350 million revolver covers near-term needs, though only $7 million YTD operating cash flow questions the $75-95 million FCF guide. Management’s $55 million synergy target is critical to restoring EBIT; execution risk remains high.

TL;DR: Elevated leverage, rising rates, and integration friction tilt risk profile negative despite synergy upside.

Net leverage nearing 5× and 7.25% secured notes amplify sensitivity to rate moves; a 25 bp SOFR uptick adds ~$2 million annual interest. Integration spending and a $12 million inventory step-up already cut operating cash, and $20 million planned rationalisation may strain relations with European labour forces. Foreign-currency exposure remains material; a 10% FX move could shave $2 million from quarterly net income despite hedges. Environmental liabilities ($18 million Fox River) and a contingent $56 million tax claim create additional tail risks. Overall credit quality hinges on timely synergy capture and margin recovery.

Magnera (MAGN) Q3 FY25 10-Q evidenzia una crescita post-fusione ma una redditività sotto pressione. Le vendite nette sono aumentate del 51% su base annua, raggiungendo 839 milioni di dollari (YTD 2,37 miliardi di dollari, +45%), principalmente grazie all'acquisizione di Glatfelter a novembre 2024; il volume organico è diminuito di circa il 5%. Il costo del venduto è aumentato del 53%, comprimendo il margine e riducendo l'utile operativo del 24% a 13 milioni di dollari. Un nuovo indebitamento da 1,99 miliardi di dollari ha portato le spese per interessi trimestrali a 37 milioni di dollari, trasformando il trimestre in una perdita di 18 milioni di dollari (-0,51 dollari per azione) rispetto a un utile di 19 milioni dell'anno precedente; la perdita YTD è di 119 milioni di dollari.

La liquidità è salita a 276 milioni di dollari, ma il flusso di cassa operativo YTD è stato solo di 7 milioni; la direzione prevede ancora un flusso di cassa libero per l'anno fiscale 25 tra 75 e 95 milioni di dollari con un capex di circa 75 milioni. La leva finanziaria si avvicina ora a circa 5× EBITDA, sebbene i covenant siano esclusivamente negativi. Le spese di integrazione/ristrutturazione sono state di 14 milioni questo trimestre (69 milioni YTD); le sinergie annuali previste sono di 55 milioni e si pianifica una razionalizzazione della capacità da 20 milioni. Vista per segmento: ricavi Americas +22% a 473 milioni di dollari, margine 2,5%; ricavi Rest-of-World +118% a 366 milioni, quasi in pareggio. Un guadagno da traduzione valutaria di 50 milioni ha portato il reddito complessivo a 32 milioni. Azioni in circolazione: 35,6 milioni (6 agosto 2025).

Magnera (MAGN) Q3 FY25 10-Q destaca crecimiento tras la fusión pero rentabilidad ajustada. Las ventas netas aumentaron un 51% interanual hasta 839 millones de dólares (YTD 2,37 mil millones, +45%), principalmente por la adquisición de Glatfelter en noviembre de 2024; el volumen orgánico cayó aproximadamente un 5%. El costo de bienes vendidos subió un 53%, presionando el margen y reduciendo el ingreso operativo un 24% a 13 millones de dólares. Una nueva deuda de 1,99 mil millones de dólares elevó el gasto por intereses trimestral a 37 millones, convirtiendo el trimestre en una pérdida de 18 millones de dólares (-0,51 dólares por acción) frente a una ganancia de 19 millones el año pasado; la pérdida YTD es de 119 millones.

El efectivo aumentó a 276 millones, pero el flujo de caja operativo YTD fue solo de 7 millones; la gerencia sigue apuntando a un flujo de caja libre para el FY25 de 75-95 millones con un capex de alrededor de 75 millones. El apalancamiento ahora se acerca a ~5× EBITDA, aunque los convenios son solo negativos. Los cargos por integración/restructuración fueron de 14 millones este trimestre (69 millones YTD); las sinergias anuales esperadas son de 55 millones y se planea una racionalización de capacidad de 20 millones. Vista por segmento: ingresos en Americas +22% a 473 millones, margen 2,5%; ingresos en Rest-of-World +118% a 366 millones, casi en equilibrio. Una ganancia por traducción de moneda de 50 millones elevó el ingreso integral a 32 millones. Acciones en circulación: 35,6 millones (6 ago 25).

Magnera (MAGN) FY25 3분기 10-Q, 합병 후 규모 확대에도 수익성은 압박. 순매출은 전년 대비 51% 증가한 8억 3,900만 달러(연초부터 23억 7천만 달러, +45%)로, 주로 2024년 11월 Glatfelter 인수에 기인하며, 유기적 물량은 약 5% 감소했다. 매출원가는 53% 급증해 마진을 압박했고, 영업이익은 24% 감소한 1,300만 달러에 그쳤다. 신규 19억 9천만 달러 부채로 분기 이자 비용이 3,700만 달러로 증가해, 이번 분기는 1,800만 달러 손실(주당 -0.51달러)로 전년 1,900만 달러 이익에서 적자 전환했다; 연초부터 손실은 1억 1,900만 달러다.

현금은 2억 7,600만 달러로 증가했으나, 연초부터 영업 현금 흐름은 700만 달러에 불과하다; 경영진은 여전히 FY25 자유 현금 흐름 7,500만~9,500만 달러를 목표로 하며, 약 7,500만 달러의 자본 지출을 계획 중이다. 레버리지는 현재 약 5배 EBITDA에 근접했으며, 계약 조건은 부정적 조항만 존재한다. 통합 및 구조조정 비용은 이번 분기에 1,400만 달러(연초부터 6,900만 달러) 발생했으며, 연간 시너지 효과는 5,500만 달러, 2,000만 달러 규모의 생산능력 합리화가 계획되어 있다. 부문별로는 미주 지역 매출이 22% 증가한 4억 7,300만 달러, 마진 2.5%; 기타 지역 매출은 118% 증가한 3억 6,600만 달러로 거의 손익분기점에 도달했다. 5,000만 달러의 환율 변동 이익으로 총포괄손익은 3,200만 달러가 되었다. 발행 주식 수: 3,560만 주(2025년 8월 6일 기준).

Magnera (MAGN) Q3 FY25 10-Q met en lumière une croissance post-fusion mais une rentabilité sous pression. Les ventes nettes ont augmenté de 51 % en glissement annuel pour atteindre 839 millions de dollars (YTD 2,37 milliards, +45 %), principalement grâce à l'acquisition de Glatfelter en novembre 2024 ; le volume organique a diminué d'environ 5 %. Le coût des marchandises vendues a bondi de 53 %, comprimant la marge et réduisant le résultat d'exploitation de 24 % à 13 millions de dollars. Une nouvelle dette de 1,99 milliard de dollars a fait grimper les charges d'intérêts trimestrielles à 37 millions, entraînant une perte trimestrielle de 18 millions de dollars (-0,51 $/action) contre un bénéfice de 19 millions l'an dernier ; la perte YTD est de 119 millions.

La trésorerie est montée à 276 millions, mais le flux de trésorerie opérationnel YTD n'était que de 7 millions ; la direction vise toujours un flux de trésorerie libre FY25 de 75-95 millions avec un capex d'environ 75 millions. L'effet de levier approche désormais environ 5× l’EBITDA, bien que les engagements soient uniquement négatifs. Les charges d’intégration/restructuration se sont élevées à 14 millions ce trimestre (69 millions YTD) ; les synergies annuelles attendues sont de 55 millions et une rationalisation de capacité de 20 millions est prévue. Vue par segment : chiffre d’affaires Amériques +22 % à 473 millions, marge 2,5 % ; chiffre d’affaires Reste du Monde +118 % à 366 millions, proche de l’équilibre. Un gain de change de 50 millions a porté le résultat global à 32 millions. Actions en circulation : 35,6 millions (6 août 25).

Magnera (MAGN) Q3 FY25 10-Q zeigt Wachstum nach Fusion, aber unter Druck stehende Profitabilität. Der Nettoumsatz stieg im Jahresvergleich um 51 % auf 839 Millionen US-Dollar (YTD 2,37 Milliarden, +45 %), hauptsächlich durch die Übernahme von Glatfelter im November 2024; das organische Volumen sank um ca. 5 %. Die Herstellungskosten stiegen um 53 %, was die Marge belastete und das Betriebsergebnis um 24 % auf 13 Millionen US-Dollar drückte. Ein neuer Schuldenberg von 1,99 Milliarden US-Dollar erhöhte die Quartalszinsaufwendungen auf 37 Millionen US-Dollar, wodurch das Quartal mit einem Verlust von 18 Millionen US-Dollar (-0,51 US-Dollar je Aktie) abschloss, im Vergleich zu einem Gewinn von 19 Millionen im Vorjahr; der YTD-Verlust beträgt 119 Millionen.

Barmittel stiegen auf 276 Millionen US-Dollar, der operative Cashflow YTD betrug jedoch nur 7 Millionen; das Management peilt weiterhin einen Free Cashflow für FY25 von 75-95 Millionen US-Dollar bei etwa 75 Millionen Capex an. Die Verschuldung nähert sich nun etwa dem 5-fachen EBITDA, wobei die Covenants ausschließlich negativ sind. Integrations- und Restrukturierungskosten beliefen sich in diesem Quartal auf 14 Millionen US-Dollar (69 Millionen YTD); erwartete jährliche Synergien betragen 55 Millionen, und eine Kapazitätsanpassung von 20 Millionen ist geplant. Segmentansicht: Americas-Umsatz +22 % auf 473 Millionen US-Dollar, Marge 2,5 %; Rest-of-World-Umsatz +118 % auf 366 Millionen, nahezu ausgeglichen. Ein Währungsumrechnungsgewinn von 50 Millionen erhöhte das Gesamtergebnis auf 32 Millionen. Ausstehende Aktien: 35,6 Millionen (6. Aug. 25).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Flammer Martina M.D.

(Last) (First) (Middle)
700 US HIGHWAY 202/206

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/04/2025 M(1) 8,715 A $19.74 91,826 D
Common Stock 08/04/2025 S(1) 8,715 D $109.5 83,111 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $19.74 08/04/2025 M(1) 8,715 (2) 01/05/2033 Common Stock 8,715 $0 26,145 D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Remarks:
/s/ Martina Flammer, M.D., by Michael A. Smith as Attorney-in-fact 08/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How did Magnera (MAGN) perform financially in Q3 FY25?

Net sales rose 51% to $839 million, but higher costs and $37 million interest expense produced a $(18 million) net loss (-$0.51 per share).

Why did Magnera’s debt increase to nearly $2 billion?

The company issued an $781 million term loan and $1.3 billion of secured notes to finance the Nov-24 Glatfelter acquisition and a cash distribution to former parent Berry Global.

What synergy savings are expected from the Glatfelter transaction?

Management forecasts $55 million in annual cost synergies net of standalone costs once integration is complete.

What is Magnera’s liquidity position after the quarter?

Cash stood at $276 million with no borrowings on the $350 million revolver; leverage is ~5× EBITDA but there are no financial maintenance covenants.

What free cash flow does Magnera project for FY25?

The company guides to $75-95 million post-transaction free cash flow, assuming ~$75 million in capital expenditures.

How did each segment perform?

Americas revenue +22% to $473 m with 2.5% margin; Rest-of-World revenue +118% to $366 m, near breakeven operating income.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

21.20B
187.30M
0.75%
110.41%
5.1%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER